Copertina

International Cost‐Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced‐Stage Classic Hodgkin's Lymphoma

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Youwen Zhu, Kun Liu, Steven T. Rosen, Hong Zhu, Wei Liu
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Hematological Oncology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

A Multicenter Real‐World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30‐Positive Adult T‐Cell Leukemia‐Lymphoma
di: Masahito Tokunaga, et al.
Pubblicazione: (2025)

PET2‐Adapted Therapy in Patients With Advanced‐Stage Hodgkin Lymphoma Treated With Frontline ABVD: Searching for the Baby in the Bathwater
di: Antonio Pinto, et al.
Pubblicazione: (2024)

Efferocytosis and M2 Macrophage Polarization Gene Expression Correlates With Relapsed and Refractory Classical Hodgkin Lymphoma Patients: A Multi‐Omic Analysis
di: Juan Quarroz Braghini, et al.
Pubblicazione: (2025)

Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi‐Center Real‐Life Study
di: M. Picardi, et al.
Pubblicazione: (2024)

Nodular Lymphocyte‐Predominant Hodgkin Lymphoma: Update on Biology and Treatment
di: Peter Borchmann, et al.
Pubblicazione: (2025)

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
di: Pier Luigi Zinzani, et al.
Pubblicazione: (2025)

RETRACTION: Burkitt Lymphoma Versus Diffuse Large B‐Cell Lymphoma: A Practical Approach
Pubblicazione: (2026)

Toxicity and Tolerability of the OEPA/COPDAC Regimen in Children and Adolescents With Hodgkin Lymphoma: A Real‐World Experience
di: Hala Bekhit, et al.
Pubblicazione: (2025)

Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching‐Adjusted Indirect Analysis
di: Fenghua Gao, et al.
Pubblicazione: (2025)

Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience
di: Vittorio Ruggero Zilioli, et al.
Pubblicazione: (2024)

Comparative Effectiveness of R‐miniCOMP Versus R‐miniCHOP in Older Non‐Fit Patients With Diffuse Large B‐Cell Lymphoma: Insights From a “Fondazione Italiana Linfomi” Cohort Study
di: Alberto Bavieri, et al.
Pubblicazione: (2025)

Discovery Science highlights from the 17th International Conference on Malignant Lymphoma
di: Gabriela Forestieri, et al.
Pubblicazione: (2024)

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
di: Yutaka Shimazu, et al.
Pubblicazione: (2025)

Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target
di: Simone Ferrero, et al.
Pubblicazione: (2025)

Correction to “Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B‐Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts”
Pubblicazione: (2025)

Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT‐Lymphoma) of the Intestine: A Single Center Analysis
di: Oskar Steinbrecher, et al.
Pubblicazione: (2024)

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
di: Meirav Kedmi, et al.
Pubblicazione: (2024)

A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
di: Monia Marchetti, et al.
Pubblicazione: (2025)

Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
di: Jinyan Xiao, et al.
Pubblicazione: (2025)

Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study
di: Fuli Fan, et al.
Pubblicazione: (2025)

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma
di: Juliette Penichoux, et al.
Pubblicazione: (2025)

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
di: Yoshikazu Ikoma, et al.
Pubblicazione: (2025)

A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B‐Cell Lymphoma of Immune‐Privileged Sites
di: Ganggang Wang, et al.
Pubblicazione: (2025)

Genetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B‐Cell Lymphoma and Transformed Follicular Lymphoma
di: Rui Sun, et al.
Pubblicazione: (2026)

Causal Associations of Gut Microbiota Species With Lymphoma: A Two‐Sample Mendelian Randomization Study
di: Mei Li, et al.
Pubblicazione: (2025)

Trends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study
di: John L. Vaughn, et al.
Pubblicazione: (2026)

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
di: Inna Y. Gong, et al.
Pubblicazione: (2026)

Changes in Lean Muscle Mass, Muscle Strength, and Physical Performance Following First‐Line Chemotherapy in Patients With Lymphoma
di: Charlotte Nørregaard Grønset, et al.
Pubblicazione: (2025)

First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients
di: E. Silkenstedt, et al.
Pubblicazione: (2025)

MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B‐Cell Lymphoma
di: Yan Li, et al.
Pubblicazione: (2025)

Peripheral T‐Cell Lymphoma: What's Next?
di: Sang Eun Yoon, et al.
Pubblicazione: (2025)

Upregulated miR‐29a‐3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1
di: Tengfei Shi, et al.
Pubblicazione: (2025)

Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma—A Regression Analysis of Dose‐Response
di: Lotte Nygård, et al.
Pubblicazione: (2025)

Comprehensive Analysis of Single‐Cell and Bulk Transcriptomics Identified Regulatory T‐Cell Features as Predictors of Prognosis in Diffuse Large B‐Cell Lymphoma
di: Yaoli Cui, et al.
Pubblicazione: (2025)

Current Status of Revisions to the Lugano Classification in Lymphoma
Pubblicazione: (2025)

Combining Total Metabolic Tumor Volume With Beta‐2‐Microglobulin Levels Predicts Outcomes in High‐Burden Follicular Lymphoma Patients
di: A. Zduniak, et al.
Pubblicazione: (2024)

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2‐[ 18 F]FDG PET/CT in Advanced Mantle Cell Lymphoma
di: Domenico Albano, et al.
Pubblicazione: (2024)

Long‐Term Real‐World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results
di: Prokop Vodicka, et al.
Pubblicazione: (2025)

CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
di: J.T. Jutzi, et al.
Pubblicazione: (2025)

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
di: Minna Harmanen, et al.
Pubblicazione: (2025)